1. Abeliovich A, Chen C, Goda Y, Silva AJ, Stevens CF, Tonegawa S. Cell 1993;75:1253–1262.

2. Abeliovich A, Paylor R, Chen C, Kim JJ, Wehner JM, Tonegawa S. Cell 1993;75:1263–1271.

3. Andrews JS, Stephens DN. Pharmacol Ther 1992;47:267–280.

4. Barrett JE. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987;1493–1501.

5. Barrett JE, Gleeson S. In: Rodgers RJ, Cooper SJ, eds. 5-HT1A agonists, 5-HT3 antagonists and benzodiazepines: their comparative behavioural pharmacology. New York: Wiley, 1991;59–105.

6. Barrett JE, Vanover KE. Psychopharmacology 1993;112:1–12.

7. Barrett JE, Monaghan MM, Rosenzweig-Lipson S. Vanover KE. Drug Dev Res 1994;[in press].

8. Blundell JE. In: Eversen LL, Iversen SD, Snyder SH, eds. Handbook of psychopharmacology, new directions in behavioral pharmacology, vol 19. New York: Plenum Press, 1987;123–182.

9. Cook L, Weidley E. Ann NY Acad Sci 1957;66:740–752.

10. Cook L, Sepinwall J. Fed Proc 1975;34:1889–1897.

11. Cory-Schlechta DA, Widzowski DV, Polora MJ. Neurotoxicology 1993;14:105–114.

12. Courvoisier S, Fournel J, Ducrot R, Kolsky M, Koetschet P. Arch Int Pharmacodyn 1953;92:305–361.

13. Davis M. Pharmacol Ther 1990;24:147–165.

14. Deutsch JA. Science 1993;262:760–763.

15. Dews PB. J Pharmacol Exp Ther 1955;113:393–401.

16. Emmett-Oglesby MW, Mathis DA, Moon RTY, Lal H. Psychopharmacology 1990;101:292–309.

17. File SE. Neuropsychobiology 1985;13:55–62.

18. Gardner CR. J Pharmacol Methods 1985;14:181–187.

19. Gauvin DV, Holloway FA. Pharmacol Biochem Behav 1991; 39:521–523.

20. Geller I, Seifter J. Psychopharmacologia 1962;1:482–492.

21. Grant AGN, O'Dell TJ, Karl KA, Stein PL, Soriano P, Kandel ER. Science 1992;258:1903–1910.

22. Grant SGN, Silva AJ. Trends Pharmacol Sci 1994;17:71–75.

23. Haefely W, Martin JR, Schoch P. Trends Pharmacol Sci 1990; 11:452–456.

24. Harvey JA. In: Meltzer HY, ed. Psychopharmacology: the third generation of progress. New York: Raven Press, 1987;1485–1490.

25. Hen R, Boschert U, Lemeur M, Dierich A, Dit Amara D, Buhot MC, Segu L, Missin R, Saudou F. Soc Neurosci Abstr 1993;19:632.

26. Iversen IH, Lattal KA. Experimental analysis of behavior, parts 1 and 2. New York: Elsevier, 1991.

27. Kalin NH. Science 1989;243:1718–1721.

28. Katz JL, Goldberg SR. In: Bozarth MA, ed. Methods of assessing the reinforcing properties of abused drugs. New York: Springer-Verlag, 1987;105–115.

29. Kelleher RT, Morse WH. Ergeb Physiol Chem Exp Pharmakol 1968;60:1–56.

30. Lister RG. Pharmacol Ther 1990;46:321–340.

31. Lubinski D, Thompson T. Brain Behav Sci 1993;16:627–642.

32. Mackintosh JH, Chance MRA, Silverman AP. In: Iversen LL, Iversen SD, Snyder SH., eds. Handbook of psychopharmacology-principles of behavioral pharmacology, vol 7. New York: Plenum Press, 1977;3–35.

33. Mansbach RS, Barrett JE. J Pharmacol Exp Ther 1987;240:364–369.

34. Martin JR, Schoch P, Jenck F, Moreau J-L, Haefely WE. Psychopharmacology 1993;111:415–422.

35. McKearney JW, Barrett JE. In: Blackman DE, Sanger DJ, eds. Contemporary research in behavioral pharmacology. New York: Plenum Press, 1978;1–68.

36. Miczek KA. In: Spiegelstein MY, Levy A., eds. Behavioral models and the analysis of drug action. Amsterdam: Elsevier, 1982;225–239.

37. Miczek KA, Thompson ML, Shuster L. Science 1982;215:1520–1522.

38. Miczek KA, Tornatzky W, Vivian JA. In: Olivier B, Mos J, Slangen JL, eds. Animal models in psychopharmacology, Basel: Birkhauser Verlag, 1991;409–427.

39. Miczek KA, Weerts EM, DeBold JF, Vatne T. Psychopharmacology 1992;107:551–563.

40. Miczek KA, Weerts EM, Haney M, Tidey J. Neurosci Biobehav Rev 1994;18:97–110.

41. Miczek KA, Weerts EM, Vivian JA, Barros H. Psychopharmacology 1994{ewc MVIMG, MVIMAGE,!infinity.bmp} press.

42. Morse WH. In: Honig WK, ed. Operant behavior. New York: Appleton–Century–Crofts, 1966;52–108.

43. Nader MA, Hoffmann S, Gleeson S, Barrett JE. Behav Pharmacol 1989;1:57–67.

44. Pickens R. In: Thompson T, Dews PB, eds. Advances in behavioral pharmacology, vol 1, New York: Academic Press, 1977;229–257.

45. Pollard GT, Howard JL. Pharmacol Ther 1990;45:403–424.

46. Porsolt RD, Lenègre A, McArthur, RA. In: Olivier B, Slangen J, Mos J, eds. Animal models in psychopharmacology. Basel: Birkhauser Verlag, 1991;137–159.

47 Sanger DJ. In: Boulton A, Baker G, Martin-Iverson M., eds. Neuromethods, animal models in psychiatry II, vol 19. Clifton, NJ: Humana Press, 1991:147–198.

48. Sanger DJ, Benavides J. Psychopharmacology 1993;111:315–322.

49. Seiden LS, O'Donnell JM. In: Seiden LS, Balster RL, eds. Neurology and neurobiology, vol 13. Behavioral pharmacology: the current status. New York: Alan R. Liss. 1985;323–338.

50. Silva AJ, Paylor R, Wehner JM, Tonegawa S. Science 1992; 257:206–211.

51. Silva AJ, Stevens CF, Tonegawa S, Wang Y. Science 1992; 257:201–206.

52. Swerdlow NR, Braff DL, Taaid N, Geyer MA. Arch Gen Psychiatry 1994;51:139–154.

53. Teicher MH, Barber NI, Lawrence JM, Balderssarini RJ. In: Koob GF, Ehlers CL, Kupfer DJ, eds. Animal models of depression. Basel: Birkhauser, 1989;135–161.

54. Treit D. Neurosci Biobehav Rev 1985;9:203–222.

55. Vellucci SV, Martin PJ, Everitt BJ. J Psychopharmacol 1988;2:80–93.

56. Vivian JA, Weerts EM, Miczek KA. Psychopharmacology 1994; [in press].

57. Wahlestedt C. Trends Pharmacol Sci 1994;15:42–46.

58. Wahlestedt C, Pich EM, Koob GF, Yee F, Heilig M. Science 1993;259:528–531.

59. Willner P. Behavioural models in psychopharmacology. New York: Cambridge University Press, 1991.

60. Winslow JT, Insel TR. Trends Pharmacol Sci 1991;12:402–404.

61. Zhou L-W, Zhang S-P, Qin, Z-H, Weiss, B. J Pharmacol Exp Ther 1994;268:1015–1023.

62. Zifa E, Fillion G. Pharmacol Rev 1992;44:401–457.